AP NEWS
Press release content from BusinessWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

Global Non-alcoholic Fatty Liver Disease Therapeutics Market 2018-2022 - 16% CAGR Projection Over the Next Four Years - Technavio

October 11, 2018

LONDON--(BUSINESS WIRE)--Oct 11, 2018-- analysts forecast the global non-alcoholic fatty liver disease (NAFLD) Therapeutics market to grow at a CAGR of over 16% during the forecast period, according to their latest market research report.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181011005336/en/

Technavio analysts forecast the global NAFLD Therapeutics market to grow at a CAGR of over 16% by 2022. (Photo: Business Wire)

The strategic alliances are one of the major trends being witnessed in the . Vendors in the global NAFLD therapeutics market are regularly engaging in strategic alliances to strengthen their market position. Key vendors are strategically acquiring businesses to gain a competitive advantage in the market.

This report is available at a USD 1,000 discount for a limited time only:

According to Technavio analysts, one of the key factors contributing to the growth of the global non-alcoholic fatty liver disease therapeutics market is the increasing prevalence of NAFLD:

Global non-alcoholic fatty liver disease therapeutics market: Increasing prevalence of NAFLD

NAFLD is the most common cause of liver dysfunction and a global health problem. The prevalence of NAFLD is increasing with the rise in the prevalence of obesity in industrialized societies, and it is the most common chronic liver disorder in Western countries.

According to a senior analyst at Technavio for research on infectious and rare diseases, “In some individuals, NAFLD progresses to end-stage liver disease, leading to liver-related morbidity and mortality. The prevalence of NAFLD in Hispanics is more compared with the prevalence of the disease in Caucasians. The major risk factors associated with NAFLD are obesity, gastric bypass surgery, dyslipidemia, hypertension, and type 2 diabetes.”

Global non-alcoholic fatty liver disease therapeutics market: Segmentation analysis

The global non-alcoholic fatty liver disease therapeutics market research report provides market segmentation by route of administration (oral ROA and parenteral ROA) and by region (the Americas, EMEA, and APAC). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Among the route of administrations, the oral ROA segment held the largest market share in 2017, contributing to around 92% of the market. This ROA segment will dominate the global market throughout the forecast period.

The Americas held the largest share of the market in 2017, accounting for close to 44% share, followed by EMEA and APAC respectively. The Americas is expected to retain its dominant position during the forecast period due to the launch of new product offerings and the existence of a strong pipeline for NAFLD.

Looking for more information on this market?

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

Market ecosystem Market characteristics Market segmentation analysis

Market Sizing

Market definition Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

Regional comparison Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Vendors covered Vendor classification Market positioning of vendors Competitive scenario

About Technavio

is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at .

View source version on businesswire.com:https://www.businesswire.com/news/home/20181011005336/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Technavio Research

Copyright Business Wire 2018.

PUB: 10/11/2018 10:09 AM/DISC: 10/11/2018 10:09 AM

http://www.businesswire.com/news/home/20181011005336/en